Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-90

Hi IronPig,

This morning I spent some time reading a lengthy article on CAR-T. It actually looked at things from the perspective of the coalface on treatment, & reading this it became all the more important why safety and a lack of even expected AE’s (ie Cytokine Release Syndrome), the cost to not only to patient’s health, QOL & recovery, but also that for hospitals & LOS plus readmissions & the real costing of treatment, albeit CAR-T is expensive anyway, time & labour consuming, particularly Autologous CAR-T.

How can we get around these huge expenses & treatment challenges whilst keeping patients safe? Interesting read! Safety is such a BIG DEAL in Oncology, and not to just the teams treating them, or clinical trials, but to Payers for Health Insurance, Governments subsidising treatments & Hospitals providing care. Interesting Read…

https://www.fiercepharma.com/pharma/mid-decade-crisis-looms-car-t-cell-therapy

That $ side of healthcare. You can’t ignore it. If Azer-Cel is successful, safer & we aren’t seeing these Grade 3 or higher AE’s, then well…Community CAR-T admin may become a thing, without the need for hospital admission with CRS later on. Hope so!